What is Rivia?
Rivia, headquartered in Zurich, Switzerland, specializes in developing advanced AI-driven analytics and data infrastructure solutions. The company's technology is designed to enhance the success rate and efficiency of clinical trials within the biopharmaceutical sector. By leveraging sophisticated data processing and machine learning, Rivia aims to streamline complex trial processes, reduce time-to-market for new therapies, and improve overall research outcomes.
How much funding has Rivia raised?
Rivia has raised a total of $3.2M across 1 funding round:
Angel/Seed
$3.2M
Angel/Seed (2024): $3.2M with participation from Nina Capital and Speedinvest
Key Investors in Rivia
Nina Capital
Nina Capital is a venture capital firm specializing in early-stage health technology, providing capital to founders aiming to transform healthcare through information technology.
Speedinvest
Speedinvest is a European venture capital fund focused on pre-Seed, Seed, and early-stage tech startups, offering capital and hands-on support across sectors including Health Tech and Deep Tech.
What's next for Rivia?
With this major strategic investment, Rivia is poised for accelerated growth and further innovation in the biopharma tech landscape. The backing from prominent investors suggests a strong market validation for Rivia's unique approach to clinical trial optimization. Future developments are likely to focus on expanding its AI capabilities, enhancing its data infrastructure, and broadening its market reach to support more biopharmaceutical companies in their quest for groundbreaking medical advancements. This strategic financing will enable Rivia to scale its operations and solidify its position as a leader in AI-powered biopharma analytics.
See full Rivia company page
